Schilling, Hannah-Lou and Hutchinson, James A. and Haferkamp, Sebastian (2022) Prediction of immune checkpoint blockade-related hepatitis in metastatic melanoma patients. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 20 (6). pp. 773-775. ISSN 1610-0379, 1610-0387
Full text not available from this repository. (Request a copy)Abstract
The introduction of clinical antibodies against programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has revolutionized cancer treatment. Immune checkpoint blockade has enormous therapeutic potential and is widely prescribed for treating various cancers. However, immune-related adverse events in checkpoint blockade-treated patients are common and limit its clinical application. Despite efforts to understand the etiology of immune-related adverse events, the underlying cellular reactions remain elusive. Recently, our group identified a subset of patients with metastatic melanoma that are predisposed to hepatitis after combined PD-1 and CTLA-4 blockade. These patients are characterized by pre-treatment expansion of effector memory CD4+ T cells (T-EM cells) in blood. We attributed this expansion to chronic or recurrent subclinical immune responses against cytomegalovirus (CMV) infection. Accordingly, baseline expansion of T-EM cells is a reliable biomarker of hepatitis risk that identifies a subgroup of patients who might benefit from prophylactic CMV treatment with valganciclovir.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | IPILIMUMAB; THERAPY |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 12 Oct 2023 09:08 |
| Last Modified: | 12 Oct 2023 09:08 |
| URI: | https://pred.uni-regensburg.de/id/eprint/56765 |
Actions (login required)
 |
View Item |
